Seraxis
Seraxis is a private biotechnology company launched in 2013, located in Germantown, Maryland. Its mission is to develop practical and potent cell replacement therapies for insulin-dependent diabetes. The company has developed novel cell and immune-evasion technologies to reverse diabetes in animal models and is working to advance these therapies to the clinic. Seraxis is engaged in developing therapies such as pancreatic organoids and islet cell tech, with a focus on stem cell-derived treatments for type 1 diabetes. It has received various grants, completed GMP quality system audits, and is involved in clinical studies and collaborations to bring its therapies into clinical practice. The company is also active in publishing research and presenting at conferences.
Industries
Nr. of Employees
small (1-50)
Seraxis
20400 Century Blvd, Suite 150, Germantown, MD 20874
Patents
Macro-encapsulated therapeutic cells, devices, and methods of using the same
US-11141508-B2
View DetailsStem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
US-9968639-B2
View DetailsMethod for generating non-pluripotent progenitors of surrogate pancreatic cells
US-9474772-B2
View Details
Macro-encapsulated therapeutic cells, devices, and methods of using the same
US-11141508-B2
View DetailsStem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
US-9968639-B2
View DetailsMethod for generating non-pluripotent progenitors of surrogate pancreatic cells
US-9474772-B2
View DetailsProducts
SR-02 clinical candidate (replacement islets)
A clinical-stage cell therapy candidate intended as a replacement islet product for treatment of Type 1 diabetes; advanced to an FDA IND allowance for a clinical study.
Pancreatic organoid / pancreatic cluster platform (preclinical)
Preclinical platform composed of synthetic replacement endocrine clusters or pancreatic organoids developed to replace missing islets and control blood glucose in animal models.
SR-02 clinical candidate (replacement islets)
A clinical-stage cell therapy candidate intended as a replacement islet product for treatment of Type 1 diabetes; advanced to an FDA IND allowance for a clinical study.
Pancreatic organoid / pancreatic cluster platform (preclinical)
Preclinical platform composed of synthetic replacement endocrine clusters or pancreatic organoids developed to replace missing islets and control blood glucose in animal models.
Services
Engagements with external organizations for research collaborations, licensing of technologies, and co-development partnerships to advance cell replacement therapies.
Engagements with external organizations for research collaborations, licensing of technologies, and co-development partnerships to advance cell replacement therapies.
Expertise Areas
- Stem cell differentiation and beta-cell generation
- Pancreatic organoid and cluster development
- Preclinical efficacy testing in diabetes models
- Immuno-engineering for cell transplantation
Key Technologies
- Pluripotent stem cell differentiation
- Pancreatic organoids / cluster engineering
- Cell transplantation / islet replacement
- Immune-evasion engineering
News & Updates
Seraxis will present an update on its pancreatic organoid candidate for the functional cure of T1D at the 59th Annual Meeting of the EASD.
Seraxis has received FDA IND allowance for its SR-02 replacement islets for Type 1 Diabetes.
Seraxis' manufacturing suite completes GMP quality system audit ahead of IND filing and transplantation.
Research on pluripotent stem cells capable of reversing diabetes in rodents.
A review of lessons learned from clinical trials in developing stem cell therapies for Type 1 Diabetes.
Seraxis publishes preclinical data for its SR-02 therapy for insulin-requiring diabetes.
Seraxis will present an update on its pancreatic organoid candidate for the functional cure of T1D at the 59th Annual Meeting of the EASD.
Seraxis has received FDA IND allowance for its SR-02 replacement islets for Type 1 Diabetes.
Seraxis' manufacturing suite completes GMP quality system audit ahead of IND filing and transplantation.
Research on pluripotent stem cells capable of reversing diabetes in rodents.
A review of lessons learned from clinical trials in developing stem cell therapies for Type 1 Diabetes.
Seraxis publishes preclinical data for its SR-02 therapy for insulin-requiring diabetes.